Boehringer initiates trial of targeted therapy to treat Covid-19 patients

The TRPC6 inhibitor may alleviate the damage to the lung and decrease the risk or severity of acute respiratory complications in Covid-19 patients. Credit: MostafaElTurkey36 on Pixabay.



  • Boehringer